Tumor-infiltrating leukocytes (TILs) comprised 16 ± 2% (mean ± sem) and 17 ± 2% of CD4+ and CD8+ T cells, respectively, and these proportions were not significantly different between the various treatment groups (Supplementary Fig. 5a). The gene discussed is CD4; the disease is neoplasm.